NICE insiders criticise Alzheimer's drug decision

The National Institute for Health and Clinical Excellence has been criticised by its own senior advisers for not listening to experts when deciding to limit the use of the only drugs available in the UK for Alzheimer's disease.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here